The most researched ligand has been CCL16 whose increased expression has shown an anti-cancer effect in mouse breast cancer [60,245], and colon carcinoma [245], and prostate cancer [246] due to an increase in the infiltration of the tumor by CD4+ T cells, CD8+ T cells, and DC. Here, CD4 is linked to colon carcinoma.